Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Poitiers – page 47

623 clinical trials in Poitiers, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Poitiers at a glance
623
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

623 trials in Poitiers

Open in trial search

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Neoplasm

Not recruiting

Study of ASP1570 Alone or with Pembrolizumab for Adults with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP1570
  • Sponsor:Astellas Pharma Global Development Inc.

Pulmonary arterial hypertension

Not recruiting

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on the Effects of NMRA-335140 for Adults with Major Depressive Disorder

Not recruiting
Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Parkinson's disease

Not recruiting

Study on the Long-Term Safety of ND0612 (Carbidopa, Levodopa) Infusion for Patients with Advanced Parkinson's Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carbidopa
  • Sponsor:Neuroderm Ltd.

Study on Long-term Safety and Effectiveness of NMRA-335140 for Patients with Major Depressive Disorder

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Waldenstrom's macroglobulinaemia

Not recruiting

Study of CLR 131 for Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iopofosine (131I)
  • Sponsor:Cellectar Biosciences Inc.

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Sunvozertinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR or HER2 Mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sunvozertinib
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Poitiers

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and various advanced cancers. Studies are evaluating novel therapeutic combinations and treatment strategies for better patient outcomes.

  • Advanced Gastric Cancer Treatments
  • Pancreatic Adenocarcinoma Therapy
  • Myelodysplastic Syndromes

Several trials are investigating targeted therapies and immunotherapy approaches for various cancer types.

02 Neurological Studies

Research focusing on essential tremor treatments and innovative therapeutic approaches. Clinical trials are evaluating new medications for movement disorders.

  • Movement Disorders
  • Neurological Conditions
  • Early Psychosis Treatment

Studies aim to improve patient quality of life through novel therapeutic interventions.

03 Transplant Medicine

Advanced research in kidney transplantation and post-transplant care, including studies on antibody-mediated rejection prevention and treatment strategies.

  • Organ Transplantation
  • Immunosuppression Protocols
  • Rejection Prevention

Trials focus on improving long-term outcomes for transplant recipients.

04 Critical Care Medicine

Studies evaluating postoperative care and pain management in critical care settings, including innovative approaches to patient comfort and recovery.

  • Pain Management
  • Postoperative Care
  • Patient Comfort Optimization

Research aims to enhance patient comfort and recovery in intensive care settings.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.